---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-062026"
form_type: "8-K"
ticker: "TMCI"
cik: "0001630627"
company_name: "TREACE MEDICAL CONCEPTS, INC."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:47:59.556450+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Treace Q3 revenue $40.8M (+23% YoY); FY2023 guidance cut to $182-186M from $191-197M

## Summary
- Q3 revenue $40.8M (+23% YoY) driven by higher kit volume and record ASP of $6,311.
- Net loss widened to $17.5M ($0.28/sh) from $12.1M ($0.22/sh) in Q3 2022.
- Adjusted EBITDA loss of $9.2M vs $8.6M loss a year ago; expects positive adj. EBITDA in Q4.
- Full-year 2023 revenue guidance lowered to $182-186M (28-31% growth) from $191-197M.
- Surgeon base grew 21% to 2,691; new technologies launched including Gen 2 SpeedPlate.

## SEC filing metadata
- accession: 0000950170-23-062026
- form_type: 8-K
- ticker: TMCI
- cik: 0001630627
- company_name: TREACE MEDICAL CONCEPTS, INC.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630627/000095017023062026/0000950170-23-062026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630627/000095017023062026/tmci-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-062026
- JSON: https://secwatch.observer/filing/0000950170-23-062026.json
- Plain text: https://secwatch.observer/filing/0000950170-23-062026.txt

## Key facts
- Earnings Releases
  TREACE MEDICAL CONCEPTS, INC. reported third quarter ended September 30, 2023 results: revenue $40.8 million, net income ($17.5) million, or ($0.28) per share, EPS ($0.28) per share. Guidance lowered.
  - Period: third quarter ended September 30, 2023
  - Revenue: $40.8 million
  - Net income: ($17.5) million, or ($0.28) per share
  - EPS: ($0.28) per share
  - Guidance: lowered
  - Result: reported results
  source text: through its Lapiplasty ® 3D Bunion Correction ® Procedure, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights: • Revenue of $40.8 million in the third quarter, a 23% increase over same period last year and a 36% increase year to date over prior year • Blended average revenue per Lapiplasty ® procedure kit sold was
  evidence_url: https://www.sec.gov/Archives/edgar/data/1630627/000095017023062026/0000950170-23-062026-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.